RxDoctor Payments Data

Shakhia Grant, APRN

Psychiatric/Mental Health · Jacksonville, FLNPI 1851871024

Payments from drug & device makers

$390in general payments, 2019–2025

Across 23 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$96
  • Johnson & Johnson$61
  • Otsuka America Pharmaceutical, Inc.$60
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$35
  • Takeda Pharmaceuticals U.S.A., Inc.$34
  • Eisai Inc.$31
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$390100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$390 in reported general payments places this provider in the 35th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$6,715
Medicare patients
18
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl55$82,711
CaplytaLumateperone Tosylate19$32,859
Abilify MaintenaAripiprazole11$31,080
Aripiprazole91$13,780
BelsomraSuvorexant26$13,592
Quetiapine Fumarate48$9,727
VyvanseLisdexamfetamine Dimesylate12$4,686
Atomoxetine Hcl12$3,397
Vilazodone Hcl11$2,722
Paliperidone ErPaliperidone16$2,234
Bupropion XlBupropion Hcl103$1,898
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$1,570
Risperidone59$1,566
Clonazepam122$1,297
Ziprasidone Hcl12$1,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$96$82,71155 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$35$32,85919 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$60$31,08011 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$34$4,68612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →